Format

Send to

Choose Destination
Cancer Immunol Immunother. 2016 Jul;65(7):797-804. doi: 10.1007/s00262-015-1783-4. Epub 2016 Jan 2.

PD-L1-specific T cells.

Author information

1
Center for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, 2730, Herlev, Denmark.
2
Center for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, 2730, Herlev, Denmark. mads.hald.andersen@regionh.dk.
3
Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. mads.hald.andersen@regionh.dk.

Abstract

Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.

KEYWORDS:

Anti-Tregs; CITIM 2015; Cancer vaccines; PD-L1; PD-L1-specific T cells

PMID:
26724936
DOI:
10.1007/s00262-015-1783-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center